(3-hydroxymethyl-phenyl)-carbamic acid ethylester | 81863-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-hydroxymethyl-phenyl)-carbamic acid ethylester
• 英文别名: ethyl (3-hydroxymethylphenyl)carbamate；ethyl N-[3-(hydroxymethyl)phenyl]carbamate
• CAS: 81863-43-6
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD12818559
• 分子量: 195.218
• InChiKey: YEUDKWHJWWWZBG-UHFFFAOYSA-N

物化性质

• 沸点：
  289.7±23.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-hydroxymethyl-phenyl)-carbamic acid ethylester 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl (3-chloromethylphenyl)carbamate
  参考文献：
  名称：

  Pyridiazinone Derivatives for the Treatment of Tumours

  摘要：

  式（I）中的化合物，其中R1、R2和R3具有权利要求1中指示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶，并可用于治疗肿瘤。

  公开号：

  US20080293719A1
• 作为产物：
  描述：

  3-氨基苯甲醇 、 氯甲酸乙酯 以 二氯甲烷 为溶剂， 生成 (3-hydroxymethyl-phenyl)-carbamic acid ethylester
  参考文献：
  名称：

  PYRIDAZINONE DERIVATIVES

  摘要：

  式（I）的化合物，其中R1、R2和R3具有权利要求1中指示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶，并可用于治疗肿瘤。

  公开号：

  US20100179148A1

文献信息

• ARYL ETHER PYRIDAZINONE DERIVATIVES
  申请人：Stieber Frank

  公开号：US20100179149A1

  公开（公告）日：2010-07-15

  Compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 , R 5 and X have the meanings indicated in claim 1 , are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

  公式I中的化合物，其中R1、R2、R3、R4、R5和X的含义如权利要求1所示，是酪氨酸激酶的抑制剂，特别是Met激酶，并可用于治疗肿瘤等疾病。
• Azole Derivatives With Antimuscarinic Activity
  申请人：Peretto Ilaria

  公开号：US20090005364A1

  公开（公告）日：2009-01-01

  The present invention relates to compounds of formula (I) wherein R1, R2, x, X, Y and B are as defined in the description for the treatment of muscarinic acetylcholine receptor mediated diseases, in particular M3 muscarinic receptor mediated diseases.

  本发明涉及式（I）的化合物，其中R1，R2，x，X，Y和B如所述的描述中所定义，用于治疗肌肉型乙酰胆碱受体介导的疾病，特别是M3肌肉型受体介导的疾病。
• Pyridazinone derivatives
  申请人：Stieber Frank

  公开号：US08367668B2

  公开（公告）日：2013-02-05

  Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.

  公式（I）的化合物，其中R1、R2和R3具有权利要求1中所示的含义，是酪氨酸激酶抑制剂，特别是Met激酶抑制剂，可用于治疗肿瘤等疾病。
• Aryl ether pyridazinone derivatives
  申请人：Stieber Frank

  公开号：US08445489B2

  公开（公告）日：2013-05-21

  Compounds of the formula I, in which R1, R2, R3, R4, R5 and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.

  公式I中的化合物，其中R1，R2，R3，R4，R5和X具有权利要求1中指示的含义，是酪氨酸激酶的抑制剂，特别是Met激酶，并可用于肿瘤的治疗，等等。
• Electrogenerated Superoxide-Activated Carbon Dioxide. A New Mild and Safe Approach to Organic Carbamates
  作者：Maria Antonietta Casadei、Franco Micheletti Moracci、Giovanni Zappia、Achille Inesi、Leucio Rossi

  DOI：10.1021/jo970308h

  日期：1997.10.1

  The electrochemical reduction of O-2 (E = -1.0 V vs SCE) in dipolar aprotic solvents in the presence of CO2 gave a carboxylating reagent (O-2(.-)/CO2) able to convert amines and different types of their derivatives into carbamates. Primary and secondary aliphatic and aromatic amines were converted into the corresponding ethyl carbamates by the addition of EtI to the carbamate anions generated in the first step of the reactions. The yields were dependent on the nucleophilicity of the nitrogen atom. beta-Bromoethyl- and propylamine gave 2-oxazolidinone and tetrahydro-1,3-oxazin-2-one in moderate yields. N-Acyl or N-(alkoxycarbonyl)alkylamines bearing a leaving group at the beta position of the alkyl substituent were converted into 3-substituted-2-oxazolidinones in high yields. By using chiral substrates, enantiopure 3-alkoxycarbonyl(or acyl)-4-substituted oxazolidin-2-ones (70-85% isolated yields) were obtained. This represents a new mild and safe route to these important auxiliaries for asymmetric synthesis. Some limitations of the process are also evidenced and accounted for.